Variabilität des Therapieansprechens von Gemcitabin bei Pankreaskarzinom: Identifizierung relevanter Genpolymorphismen

Schaudinn, Alexander

Retrospektive Studie bei Patienten mit Pankreaskarzinom

dc.contributor.advisor	Brockmöller, Jürgen Prof. Dr.	de
dc.contributor.author	Schaudinn, Alexander	de
dc.date.accessioned	2013-01-23T09:53:28Z	de
dc.date.available	2013-02-04T23:50:07Z	de
dc.date.issued	2013-01-23	de
dc.identifier.uri	http://hdl.handle.net/11858/00-1735-0000-000D-F18A-F	de
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-3369
dc.language.iso	deu	de
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/
dc.subject.ddc	610	de
dc.title	Variabilität des Therapieansprechens von Gemcitabin bei Pankreaskarzinom: Identifizierung relevanter Genpolymorphismen	de
dc.title.alternative	Retrospektive Studie bei Patienten mit Pankreaskarzinom	de
dc.type	doctoralThesis	de
dc.title.translated	Variability of therapy response in gemcitabine treated pancreatic carcinoma: Identifying relevant gene polymorphisms	de
dc.contributor.referee	Brockmöller, Jürgen Prof. Dr.	de
dc.date.examination	2013-01-28	de
dc.subject.gok	Klinische Pharmakologie	de
dc.description.abstracteng	Gene polymophisms could play an important role in the variability of therapy response in gemcitabine treated patients with pancreatic carcinoma. The retrospective study showed that a polymorphism in ENT-1, a carrier of gemcitabine, had an influence on overall survival.	de
dc.contributor.coReferee	Liersch, Torsten PD Dr.	de
dc.title.alternativeTranslated	Retrospectiv study in patients with pancreatic carcinoma	de
dc.subject.eng	Gemcitabine	de
dc.subject.eng	Gene Polymorphism	de
dc.subject.eng	ENT1	de
dc.subject.eng	Pancreatic Carcinoma	de
dc.identifier.urn	urn:nbn:de:gbv:7-11858/00-1735-0000-000D-F18A-F-5	de
dc.affiliation.institute	Medizinische Fakultät	de
dc.description.embargoed	2013-02-04	de
dc.identifier.ppn	737346035	de